Clinical studiesChromium picolinate (cas 15713-60-7) attenuates hyperglycemia-induced oxidative stress in streptozotocin-induced diabetic rats

Add time:09/07/2019    Source:sciencedirect.com

Chromium picolinate is advocated as an anti-diabetic agent for impaired glycemic control. It is a transition metal that exists in various oxidation states and may thereby act as a pro-oxidant. The present study has been designed to examine the effect of chromium picolinate supplementation on hyperglycemia-induced oxidative stress. Diabetes was induced in male Wistar rats by a single intraperitoneal injection of streptozotocin (50 mg/kg body weight) and chromium was administered orally as chromium picolinate (1 mg/kg body weight) daily for a period of four weeks after the induction of diabetes. As is characteristic of diabetic condition, hyperglycemia was associated with an increase in oxidative stress in liver in terms of increased lipid peroxidation and decreased glutathione levels. The activity of antioxidant enzymes like superoxide dismutase, catalase and glutathione reductase were significantly reduced in liver of diabetic animals. Levels of α-tocopherol and ascorbic acid were found to be considerably lower in plasma of diabetic rats. Chromium picolinate administration on the other hand was found to have beneficial effect in normalizing glucose levels, lipid peroxidation and antioxidant status. The results from the present study demonstrate potential of chromium picolinate to attenuate hyperglycemia-induced oxidative stress in experimental diabetes.

We also recommend Trading Suppliers and Manufacturers of Chromium picolinate (cas 15713-60-7). Pls Click Website Link as below: cas 15713-60-7 suppliers

Prev:Quantitative determination of Chromium picolinate (cas 15713-60-7) in animal feeds by solid phase extraction and liquid chromatography-tandem mass spectrometry
Next:Mutagenicity of Chromium picolinate (cas 15713-60-7) and its components in Salmonella typhimurium and L5178Y mouse lymphoma cells)